Acute promyelocytic leukemia risk factors: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (6 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Acute promyelocytic leukemia}} | {{Acute promyelocytic leukemia}} | ||
{{CMG}} {{shyam}} | {{CMG}} {{shyam}} {{AE}} {{S.G.}}; {{GRR}} {{Nat}} | ||
==Overview== | ==Overview== | ||
[[Risk factor|Risk factors]] for acute promyelocytic leukemia are similar to | [[Risk factor|Risk factors]] for acute promyelocytic leukemia are similar to risk factors for [[acute myeloid leukemia]]. These include advanced [[age]], [[benzene]] exposure, prior [[myelodysplastic syndrome]], and [[germline]] [[mutation]]<nowiki/>s. | ||
==Acute promyelocytic leukemia risk factors== | ==Acute promyelocytic leukemia risk factors== | ||
*'''Advanced age''' | *'''Advanced age''' | ||
*'''Benzene''' | **This is the most common risk factor for acute leukemia. | ||
*'''Prior myelodysplastic syndrome''': [[Myelodysplastic syndrome]] is a disorder characterized by ineffective hematopoiesis, defective maturation of blood cells, and peripheral cytopenias. Antecedant [[myelodysplastic syndrome]] is implicated in some forms of acute leukemia, such as [[acute myeloid leukemia]]. Myelodysplastic syndrome is a precursor for leukemia, as this disease is characterized by the presence of dysplastic or cancerous cells that do not meet the requirements for a formal diagnosis of leukemia.<ref name="pmid23980065">{{cite journal| author=Malcovati L, Hellström-Lindberg E, Bowen D, Adès L, Cermak J, Del Cañizo C et al.| title=Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. | journal=Blood | year= 2013 | volume= 122 | issue= 17 | pages= 2943-64 | pmid=23980065 | doi=10.1182/blood-2013-03-492884 | pmc=3811170 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23980065 }} </ref> | **Elderly patients are more likely to develop [[myeloid leukemia]], due to a longer duration and opportunity for mutations to accumulate in cells. | ||
*'''Germline mutations''' | **These mutations are more likely to accumulate in [[hematopoietic]] [[Stem cell|stem cells]] through a process called clonal evolution.<ref name="pmid25056697">{{cite journal| author=Grove CS, Vassiliou GS| title=Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer? | journal=Dis Model Mech | year= 2014 | volume= 7 | issue= 8 | pages= 941-51 | pmid=25056697 | doi=10.1242/dmm.015974 | pmc=4107323 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25056697 }} </ref> | ||
*'''Benzene''' | |||
**Benzene is a chemical [[solvent]] and [[aromatic]] [[hydrocarbon]], for which exposure is a significant risk factor for [[acute leukemia]].<ref name="pmid22166497">{{cite journal| author=McHale CM, Zhang L, Smith MT| title=Current understanding of the mechanism of benzene-induced leukemia in humans: implications for risk assessment. | journal=Carcinogenesis | year= 2012 | volume= 33 | issue= 2 | pages= 240-52 | pmid=22166497 | doi=10.1093/carcin/bgr297 | pmc=3271273 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22166497 }} </ref> | |||
*'''Prior myelodysplastic syndrome''': | |||
**[[Myelodysplastic syndrome]] is a [[Disorder (medicine)|disorder]] characterized by ineffective [[hematopoiesis]], defective [[maturation]] of [[Blood cell|blood cells]], and peripheral [[Cytopenia|cytopenias]]. | |||
**Antecedant [[myelodysplastic syndrome]] is implicated in some forms of acute leukemia, such as [[acute myeloid leukemia]]. | |||
**[[Myelodysplastic syndrome]] is a [[precursor]] for [[leukemia]], as this disease is characterized by the presence of [[Dysplasia|dysplastic]] or [[cancerous]] [[cells]] that do not meet the requirements for a formal [[diagnosis]] of [[leukemia]].<ref name="pmid23980065">{{cite journal| author=Malcovati L, Hellström-Lindberg E, Bowen D, Adès L, Cermak J, Del Cañizo C et al.| title=Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. | journal=Blood | year= 2013 | volume= 122 | issue= 17 | pages= 2943-64 | pmid=23980065 | doi=10.1182/blood-2013-03-492884 | pmc=3811170 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23980065 }} </ref> | |||
*'''Germline mutations''' | |||
**In general, [[germline]] [[predisposition]] to [[acute promyelocytic leukemia]] is rare. In patie<nowiki/>[[patient|nt]]<nowiki/>s with [[acute myeloid leukemia|acute myeloid]]<nowiki/> [[acute myeloid leukemia|leukemia]], [[germline]] [[Mutation|mutations]] in the ''[[RUNX1]]'' gene can predispose to the development of the cancer.<ref name="pmid28179279">{{cite journal| author=Sood R, Kamikubo Y, Liu P| title=Role of RUNX1 in hematological malignancies. | journal=Blood | year= 2017 | volume= 129 | issue= 15 | pages= 2070-2082 | pmid=28179279 | doi=10.1182/blood-2016-10-687830 | pmc=5391618 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28179279 }} </ref> | |||
==References== | ==References== | ||
Latest revision as of 16:15, 8 April 2019
|
Acute promyelocytic leukemia Microchapters |
|
Differentiating Acute promyelocytic leukemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Acute promyelocytic leukemia risk factors On the Web |
|
American Roentgen Ray Society Images of Acute promyelocytic leukemia risk factors |
|
Directions to Hospitals Treating Acute promyelocytic leukemia |
|
Risk calculators and risk factors for Acute promyelocytic leukemia risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2] Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [3]; Grammar Reviewer: Natalie Harpenau, B.S.[4]
Overview
Risk factors for acute promyelocytic leukemia are similar to risk factors for acute myeloid leukemia. These include advanced age, benzene exposure, prior myelodysplastic syndrome, and germline mutations.
Acute promyelocytic leukemia risk factors
- Advanced age
- This is the most common risk factor for acute leukemia.
- Elderly patients are more likely to develop myeloid leukemia, due to a longer duration and opportunity for mutations to accumulate in cells.
- These mutations are more likely to accumulate in hematopoietic stem cells through a process called clonal evolution.[1]
- Benzene
- Benzene is a chemical solvent and aromatic hydrocarbon, for which exposure is a significant risk factor for acute leukemia.[2]
- Prior myelodysplastic syndrome:
- Myelodysplastic syndrome is a disorder characterized by ineffective hematopoiesis, defective maturation of blood cells, and peripheral cytopenias.
- Antecedant myelodysplastic syndrome is implicated in some forms of acute leukemia, such as acute myeloid leukemia.
- Myelodysplastic syndrome is a precursor for leukemia, as this disease is characterized by the presence of dysplastic or cancerous cells that do not meet the requirements for a formal diagnosis of leukemia.[3]
- Germline mutations
- In general, germline predisposition to acute promyelocytic leukemia is rare. In patients with acute myeloid leukemia, germline mutations in the RUNX1 gene can predispose to the development of the cancer.[4]
References
- ↑ Grove CS, Vassiliou GS (2014). "Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer?". Dis Model Mech. 7 (8): 941–51. doi:10.1242/dmm.015974. PMC 4107323. PMID 25056697.
- ↑ McHale CM, Zhang L, Smith MT (2012). "Current understanding of the mechanism of benzene-induced leukemia in humans: implications for risk assessment". Carcinogenesis. 33 (2): 240–52. doi:10.1093/carcin/bgr297. PMC 3271273. PMID 22166497.
- ↑ Malcovati L, Hellström-Lindberg E, Bowen D, Adès L, Cermak J, Del Cañizo C; et al. (2013). "Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet". Blood. 122 (17): 2943–64. doi:10.1182/blood-2013-03-492884. PMC 3811170. PMID 23980065.
- ↑ Sood R, Kamikubo Y, Liu P (2017). "Role of RUNX1 in hematological malignancies". Blood. 129 (15): 2070–2082. doi:10.1182/blood-2016-10-687830. PMC 5391618. PMID 28179279.